Clinical studies for Lantus, a new insulin preparation presented.
Published: 2007-05-18 06:58:00
Updated: 2007-05-18 06:58:00
Sanofi-Aventis has developed a long acting insulin called Lantus (insulin glargine) made by the DNA recombinant technology, showing an efficient blood sugar control for most of Asian diabetic patients including Koreans, which was conformed to the earlier clinical results.
In the Spring confer...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
